Your browser doesn't support javascript.
loading
Kidney dysfunction due to AA amyloidosis in a morbidly obese female.
Izzedine, Hassan; Nimkar, Abhishek; Bharati, Joyita; Brocheriou, Isabelle; Mathian, Alexis; Charlotte, Frederic; Jhaveri, Kenar D; Georgin-Lavialle, Sophie.
Afiliación
  • Izzedine H; Department of Nephrology, Peupliers Private Hospital, Paris, France.
  • Nimkar A; Division of Kidney Diseases and Hypertension at Northwell Health, Donald and Barbara Zucker School of Medicine, Northwell Health, NY, USA.
  • Bharati J; Division of Kidney Diseases and Hypertension at Northwell Health, Donald and Barbara Zucker School of Medicine, Northwell Health, NY, USA.
  • Brocheriou I; Glomerular Center at Northwell, Northwell Health, NY, USA.
  • Mathian A; Department of Pathology.
  • Charlotte F; Department of Internal Medicine, Pitie Salpetriere Hospital.
  • Jhaveri KD; Department of Pathology.
  • Georgin-Lavialle S; Division of Kidney Diseases and Hypertension at Northwell Health, Donald and Barbara Zucker School of Medicine, Northwell Health, NY, USA.
Clin Nephrol Case Stud ; 11: 121-125, 2023.
Article en En | MEDLINE | ID: mdl-37533546
Kidneys are commonly involved in systemic amyloidosis. Systemic AA amyloidosis is known to be associated with states of chronic inflammation such as autoimmune conditions, chronic infections, and malignancies. Obesity is increasingly recognized to be a risk factor for low-grade, chronic inflammation. We report a 48-year-old female with morbid obesity who presented with unexplained persistent mild kidney dysfunction and low-grade proteinuria. Attempt at evaluating the cause of kidney dysfunction included performing kidney biopsy despite technical challenges. Kidney biopsy showed AA amyloidosis with predominant vascular deposition, explaining the absence of nephrotic-range proteinuria. Evaluation for secondary causes of systemic AA amyloidosis was negative. While our patient was treated with sleeve gastrectomy for morbid obesity with reasonable response, it is likely that ongoing chronic inflammation, reflected by her laboratory markers, resulted in AA amyloidosis. Treatment with anakinra, an interleukin-1 antagonist, led to improvement in the laboratory markers in the next 6 months, and her kidney function remained stable. This report highlights an important cause of kidney dysfunction in morbid obesity, an atypical presentation of AA amyloidosis, and emphasizes the value of kidney biopsy in such patients.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Risk_factors_studies Idioma: En Revista: Clin Nephrol Case Stud Año: 2023 Tipo del documento: Article País de afiliación: Francia Pais de publicación: Alemania

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Risk_factors_studies Idioma: En Revista: Clin Nephrol Case Stud Año: 2023 Tipo del documento: Article País de afiliación: Francia Pais de publicación: Alemania